false
0001178697
0001178697
2026-11-14
2026-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 14, 2026
DNA
X, INC.
(Exact
name of Registrant as Specified in Its Charter)
| Delaware |
|
001-38907 |
|
94-3336783 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
| |
|
|
|
|
4445
Eastgate Mall
Suite
200, San Diego, California |
|
|
|
92121 |
| (Address of Principal Executive
Offices) |
|
|
|
(Zip Code) |
Registrant’s
Telephone Number, Including Area Code: (661) 618-7580
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, $0.001 par value |
|
SONM |
|
The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item
5.02 | Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
On
November 14, 2026, the compensation committee (the “Committee”) of the board of directors (the “Board”) of DNA
X, Inc. (the “Company”) approved the grant of a cash award (the “Substitute Cash Grant”) to Mike Mulica, the
Company’s acting Chief Executive Officer and Executive Chairman, in lieu of an annual grant of restricted stock units (“RSUs”)
under the Company’s 2019 Equity Incentive Plan (the “EIP”) due to the unavailability of shares of common stock under
the EIP. The amount of the Substitute Cash Grant will be determined using the following methodology, which was designed to closely replicate
RSU vesting under the Company’s current non-employee director compensation policy:
Assumptions:
| (i) | A
number of cash-settled RSUs valued at $50,000, based on the fair market value of the Company’s
common stock on November 14, 2026, the date of Committee approval (the “Phantom RSUs”),
has been granted. |
| | | |
| (ii) | The
Phantom RSUs will vest in full upon the earlier of (x) the Company’s 2027 annual meeting
of stockholders and (y) a change in control of the Company (the “Vesting Event”). |
Calculation:
The
Substitute Cash Grant will equal the fair market value of the Company’s common stock at the time of the Vesting Event multiplied
by the number of Phantom RSUs and will be payable as of the Vesting Event, subject to Mr. Mulica’s continued service through such
Vesting Event.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
DNA X, INC. |
| |
|
|
| Date: November 16, 2026 |
By: |
/s/ Clayton Crolius |
| |
Name: |
Clayton Crolius |
| |
Title: |
Chief Financial Officer |